SER-262: Phase Ib started

Seres began a 24-week, double-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial to evaluate 104-108

Read the full 142 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE